He C, Liu Z, Huang J, Liu T. Therapeutic effect of 28-homobrassinolide on leukotriene synthesis in leukemia cells.
Cytotechnology 2018;
70:431-438. [PMID:
29101583 PMCID:
PMC5809672 DOI:
10.1007/s10616-017-0158-4]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 10/20/2017] [Indexed: 02/05/2023] Open
Abstract
The present study was aimed to investigate the effect of 28-homobrassinolide on leukotriene synthesis in the 2H3 cells. Cell viability was determined by using sulforhodamine B (SRB) assay. Leukotriene C4 (LTC4) and Leukotriene B4 (LTB4) were determined in the cell and cell lysates. Intracellular Ca2+ was determined in the intact cells. Phospholipases A2 (PLA2) expression was determined in the cells using immunofluorescence. LTC4 and LTB4 were tremendously increased in IgE-loaded 2H3 cells. However, these levels were significantly reduced following treatment with 28-homobrassinolide. The intracellular Ca2+ level was not altered by treatment. Expression of PLA2 was significantly reduced following treatment with 28-homobrassinolide. Taking all these data together, it is suggested that the 28-homobrassinolide may be a potential therapeutic agent to inhibit leukotriene synthesis in 2H3 cells.
Collapse